ArticleCureus2026
Real-World Effectiveness of Budesonide Monotherapy via Pressurized Metered-Dose Inhaler in Steroid-Naive Pediatric Asthma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInhaled corticosteroids (ICS) remain the cornerstone of asthma management in children. However, real-world evidence evaluating the effectiveness of budesonide monotherapy in steroid-naive pediatric patients is limited. This study aimed to assess the impact of inhaled budesonide delivered via a pressurized metered-dose inhaler (pMDI) on pulmonary function and asthma control in steroid-naive children with bronchial asthma.
methodsThis prospective observational study was conducted in the Asthma Clinic, Department of Pediatrics, King George's Medical University, Lucknow, from April 2022 to March 2023 after ethical approval. A total of 108 children aged 5-12 years with physician-diagnosed asthma were screened. After applying inclusion and exclusion criteria, 50 steroid-naive children were enrolled. Steroid-naive status was defined as no prior regular ICS use and no systemic corticosteroid exposure within the preceding three months. All participants received inhaled budesonide monotherapy at a low- to medium-dose of 200-400 μg/day, as per Global Initiative for Asthma (GINA) recommendations, via pMDI with spacer. Baseline and three-month assessments included spirometry (forced expiratory volume in one second (FEV₁), FEV₁% predicted, forced expiratory flow between 25% and 75% (FEF25-75% predicted)), Childhood Asthma Control Test (CACT), Mini Pediatric Asthma Quality of Life Questionnaire (MiniPAQLQ), and Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ). Paired comparisons were performed, and p<0.05 was considered statistically significant.
resultsSignificant improvement was observed in pulmonary function parameters after three months of budesonide therapy. Post-bronchodilator FEV₁ increased significantly (p<0.001), and FEV₁% predicted improved by 28.7% (p<0.001). FEF25-75% predicted showed a 17.1% increase, indicating improvement in small airway function. Asthma control improved substantially, with 56% of children achieving controlled asthma status at three months compared to none at baseline (p<0.001). Mean CACT scores increased significantly, accompanied by clinically meaningful improvements in MiniPAQLQ and PACQLQ scores (p<0.001 for all comparisons). Budesonide was well tolerated, with no serious adverse effects reported.
conclusionInhaled budesonide monotherapy administered via pMDI significantly improves pulmonary function, asthma control, and quality of life in steroid-naive pediatric asthma patients within three months. These findings suggest that budesonide alone is an effective and reliable controller therapy in real-world clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.